BRCA1 and triple-negative breast carcinoma: Ibrahim et al. showed that PI3K blockade using PI3K inhibitors resulted in HR impairment and sensitization towards PARP inhibition in triple negative breast carcinomas without BRCA1/2 mutations [37].